Sagent Pharmaceuticals, a Schaumburg, Ill.-based provider of specialty pharmaceutical products with a specific emphasis on the injectables market, has named Allan Oberman chief executive officer and a member of the board of directors, effective immediately upon receipt of a U.S. work visa.

Chairman of Sagent’s Board of Directors Robert J. Flanagan said, “Allan has deep knowledge and extensive experience in the global generic market. His proven ability to build value while communicating a clear and consistent vision will enable him to provide strong leadership as we look to capitalize on what we believe are significant market opportunities over the coming years. The board is confident that Allan is uniquely qualified to refine our strategy and unify the company around a global plan to accelerate growth.”

Oberman most recently was president and chief executive officer of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries. Prior to that position, Oberman held a number of senior roles with Teva including president of Eastern Europe, Middle East, Israel and Africa (EMIA), chief operating officer of The Teva International Group, and president and CEO of Teva Canada. Previously, Allan was the president of Best Foods Canada. Allan also was the vice chairman of the Canadian Generic Pharmaceutical Association (CGPA) from 2003 to 2007, chairman of CGPA in 2007 and 2008, and vice chairman of the U.S. Generic Pharmaceutical Association (GPhA) in 2014.